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INTRODUCTION 
 
Hearing impairment is the most common sensory deficit in human beings. 
It affects more than 250 million people in the world. The consequences of 
hearing impairment include difficulty in interpret of speech, often 
producing a decreased ability to communicate, delay in language 
acquisition, educational and economic drawbacks, social isolation and 
stigmatization. It may turn bad along with by medical conditions such as 
hypothyroidism, diabetes, and hyperlipidemia, among others. 
 
Hearing loss can be classified into 3 types: 
A. Conductive hearing loss 
      B.   Sensorineural hearing loss 
C.   Mixed hearing loss 
 
Hearing of an individual could by assessed by clinical and audiometric 
tests. Pure tone audiometery is a simple audiometric test which is being 
used to measure the degree of hearing impairment. 
 
Diabetes mellitus is an increasing health problem worldwide and the 
prevalence is steadily increasing. And it is more pronounced in India (an 
estimate total of about 40.9 million).  
 
 Diabetes Mellitus is a metabolic disorder. It presents because of partial or 
complete reduction of insulin levels which results in increased levels of blood 
glucose in association with long term complications which may be vascular or 
neurological. Among the metabolism disorders of glucose, diabetes is found  
commonly related to auditory disorders. It also affects metabolism of lipids 
and proteins. Though Diabetes Mellitus has various etiologies, the most 
common presentation is hyperglycemia. The physiological basis of type 2 
diabetes mellitus is a combined form of both impairment of beta cell function, 
with significant raise in peripheral levels of insulin resistance near the levels 
of receptor and post receptor. The complex arrangement of inner ear makes it 
potential target of hyperglycaemic damage. 
 
Diabetic patients are more prone to complications of hyperglycemia, as all 
body cells are exposed to high levels of plasma glucose. The organ of corti 
cells are important structures for hearing mechanism and turn out to be the 
potential target for damage, due to high glycemic levels, micro vascular 
compromise, their complex structure and arrangement. Thus screening of 
these patients at a higher risk of developing sensory neural hearing loss, will 
aid in early diagnosis and management. 
 
 
 
AIM OF STUDY 
 
1.  To Study the prevalence of Hearing loss and its association with 
Diabetes. 
2.  To assess the hearing loss in diabetics and correlate it with age and 
duration of  diabetes  
 
  
REVIEW OF LITERATURE 
 
 The pure tone hearing average in frequencies 250, 500, 1000, 2000, 
4000, 6000, 8000 Hz heard in more than 25 decibel in the ear is called as 
hearing loss. Hearing loss is a dysfunction of hearing. Its severity varies 
from mild; moderate; severe or profound. In general hearing loss can be 
divided into conductive type, sensorineural type or mixed type.[1] 
 
Hearing impairment is the most common sensory deficit in human 
populations, affecting more than 250 million people in the world. The 
consequences of hearing impairment include inability to interpret speech 
sounds, often producing a reduced ability to communicate, delay in 
language acquisition, economic and educational disadvantage, social 
isolation and stigmatization. It may be worsened by some medical 
conditions such as diabetes, hypothyroidism and possibly hyperlipidemia, 
among others.[2] 
 
Global Burden of Disease 2000 study which was published in the World 
Health Report 2001 the adult-onset hearing loss is the 2
nd
 most leading 
cause of Years lead with diseases in global level, which accounts for 
4.6% of total global YLDs [3]. 
 
 
ANATOMICAL CONSIDERATIONS: 
 
The human ear has three parts the outer, the middle and the inner 
ear. During the 6th week of embryonic life, about 6 tubercles appear near 
the 1
st
 branchial cleft. These tuberceles gradually coincide to become 
auricle. By 20
th
 week, pinna achieves adult shape. 
 
The external auditory canal forms from the 1
st
 branchial cleft. In 
the 16
 
th embryonic week, the cells multiply from below ectodermal cleft 
and forms the meatal plug. Recanalisation from this forms the epithelial 
lining in the bony meatus. Recanalisation starts deep near the tympanic 
membrane and grows outwards. External ear canal is completely formed 
in the 28
th
 week. 
 
The development of tympanic membrane is from the three 
germinal layers. The outer epithelial layer develops from the ectoderm, 
the inner mucosal layer is from the endoderm and the middle fibrous 
layer is from the mesoderm. 
 
The Eustachian tube, tympanic cavity, attic, antrum and mastoid air 
cells forms from the endoderm in the tubotympanic recess. This is found 
arising from the first and second pharyngeal pouch partially. The malleus 
and incus develops from mesoderm of the 1
st
  arch whereas stapes 
develops from the 2
nd
  arch except the footplate and the annular ligament 
which is formed from the Otic capsule. 
The inner ear is the first organ of special senses to be formed in 
man. The evolution of the inner ear starts during the 3
rd
  week of 
embryonic life and is completely from the sixteenth week. Ectoderm in 
this region of the hind brain becomes thick to form the auditory placode 
which  invaginates to become the Auditory vesicle or the Otocyst. This 
then differentiates to form the endolymphatic duct and sac, the 
semicircular ducts, saccule, the utricle and the cochlea. The cochlea is 
fully developed by 20
th
 week of gestation.  
 
The external ear consists of the auricle or pinna, external acoustic 
canal and tympanic membrane. The entire pinna, except the lobule, and 
the outer part of external acoustic meatus are derived from a single 
framework of yellow elastic cartilage which is covered by skin. This is 
attached tightly to the perichondrium over the lateral surface and it is 
loosely attached over the medial surface. The external acoustic canal 
starts below the concha till the tympanic membrane. It measures around 
24mm in its posterior wall. There are two parts of the canal namely the 
cartilaginous and the bony part. The cartilaginous part measures about 
8mm and is the outer part of the canal. The skin, covering this region is 
thicker and it contains ceruminous glands and pilosebaceous glands. The 
hair follicles are limited only in the outer part of canal. The bony part 
forms inner two- thirds and measures 16mm. Skin lining this region is 
thiner and it continuity with the tympanic membrane. It is free of hair 
follicles and cerumin containing gland. 
 
The tympanic membrane forms the division from the external canal 
and the middle ear. They are placed obliquity, measures about 9- 10mm 
in height. It is divided into two parts,the pars tensa and the pars flaccida. 
Pars tensa forms most of the tympanic memebrane . The central part is 
withdrawn inwards near the tip of the malleus and this region is called 
Umbo.  Bright cone of light is usually found radiating from the tip of 
malleus extending till the periphery of the anteroinferior quadrant. Pars 
flaccid also known as Sharpnel’s membrane is situated above the lateral 
process of malleus between the notch of Rivinus and the anterior and 
posterior malleal folds. It appears pink and not so taut.  The tympanic 
membrane is divided into 3 layers (i) The epithelial layer is outer most, 
found in continuity with the meatus skin lining (ii) The mucosal layer is 
innermost, continous from the mucosa in the middle ear. (iii)  Fibrous 
layer is in middle, encloses the handle of malleus. This layer has 3 types 
of fibers, namely the radial, circular and parabolic fibers. 
 
The middle ear along with eustachian tube, aditus, antrum and mastoid air 
cells is called the middle ear cleft. It is covered by mucosa and it is filled 
with air. Middle ear is compared to a box with six sides with a roof, a 
floor, lateral, medial, anterior and posterior walls. The mastoid antrum is 
the largest cell and it contains air and communicates with the attic 
through the aditus in the upper part. The tegmen antri forms the roof and 
this separates it from the middle cranial fossa. Aditus is an opening 
through which the attic communicates with the antrum. The facial nerve 
is found just below the aditus 
 
Three ossicles are found in the middle ear. They are the malleus, 
the incus and the stapes. Malleus has a head, handle, neck, a lateral 
process and anterior process. The head and neck of malleus lie in the 
attic. The lateral process forms a knob- like projection and gives 
attachment to anterior and posterior malleal folds. The incus consists of 
the body and short process both of which lie in the attic. The long process 
is attached to the head of stapes. The stapes is divided into the head, foot 
plate, neck, anterior and posterior crura. It is attaches to the oval window 
by the annular ligament. The ossicles direct the sound energy from the 
tympanic membrane into the oval window and then to the inner ear. 
 
 
The internal ear also called the labyrinth is an organ of importance for 
balance and hearing. It contains the bony and membranous labyrinth. 
Membranous labyrinth contains fluid which is clear called endolymph. 
Perilymph is seen in the space seperating the membranous and bony 
labyrinth . The bony labyrinth has three parts: the vestibule, the 
semicircular canals and the cochlea. The membranous labyrinth consists 
of the cochlear duct, the utricle, saccule, the endolymphatic duct and sac 
and three semicircular ducts, 
 
The organ of Corti is situated on the basilar membrane. It is the 
sense organ of hearing and balance. The organ of Corti contains the 
tunnel of Corti , hair cells , supporting cells , tectorial membrane .  The 
inner and outer rods form the tunnel of corti. The fluid inside is called the 
cortilymph. The hair cells act as a significant receptor cells for  hearing. It 
transforms sound to electrical energy. Inner hair cells are arranged in a 
single row while the outer hair cells are placed in 3 to 4 rows. The inner 
hair cells are richly supplied by afferent cochlear fibres and it is probably 
more important in transmission of auditory impulses. The outer hair cells 
mostly receive efferent innervations from the Olivary complex. It is 
concerned with modulating the function of the inner hair cells.   There are 
a total of 3500 inner hair cells and they are flask shaped . The outer hair 
cells are 12000 in number and they are cylindrical. 
  
Figure 1: Organ of corti 
 
 
 
 
 
 
 
Acoustics: 
Sound is a form of energy produced by a vibrating object. A sound wave 
consists of compression and rarefaction of molecules of the medium in 
which it travels. The sound velocity differs from media to media. Sound 
travels fastest in solid medium. 
 
Frequency is the number of cycles per second. The unit of frequency is 
Hertz (Hz) named after Heinrich Rudolf Hertz who was a German 
scientist. A sound of 1000 Hz means 1000 cycles per second. 
 
Pure tone is a single frequency of sound. In pure-tone audiometry the 
threshold of hearing is measured in decibles for varied pure tones ranging 
from 125 to 8000. 
 
Complex sound is a sound which contains many frequency. Human voice 
is an example of complex sound. 
 
Pitch is a subjective sensation which is produced by frequency of sound. 
More the frequency, more is the pitch. 
 
A complex sound consists of basic frequency, i.e. the lowest frequency in 
which a source is set into vibrations. Frequencies above this level are 
termed as overtones. The latter determines the quality or the timber of 
sound. 
Intensity is the sound strength which determines its loud nature. It is 
usually calculated in decibles. At an approximate distance of 1 metre, the 
intensity of 
Whisper                       = 30 dB 
Normal conversation   = 60 dB 
Shout                           = 90 dB 
Discomfort of the ear  = 120 dB 
Pain in the ear              = 130 dB 
 
Loudness is a sensation that is subjective, which is produced by intensity. 
More the intensity of sound, more is the loudness. 
 
Decibel(dB) is denoted as 1/10
th
 of a bel and it is named in remembrance 
of Sir Alexander Graham Bell. It is the logarithmic ratio among two 
sounds which is the sound being detailed and sound of reference. Sound 
can be measured as power. Level of sound pressure is the measure of 
sound in audiology. SPL is compared in reference of sound which 
containd an SPL of 0.0002 dynes/cm2 or 20µ Pa (micropascals) this 
approximately corresponds to the threshold in normal subjects with 
hearing under normal limits at 1000 Hz. Decibel is used to avoid large 
figures of sound pressure level. 
                                                                   Power of S1 
                           Sound in dB = 10 log  ---------------------- 
                                                                    Power of S0            
Noise is descirbed as an aperiodic complex of sound. The three varities of 
noise are: 
 
(a) White noise: this consists of all the frequencies in the entire audible 
spectrum. It can be compared to white light which contains all the 
colours in the visible spectrum. This is a broad-band noise 
generally used for purpose of masking. 
 
(b) Narrow band noise: This is white noise that contains specific 
frequencies which are above and below the given noise which is 
filtered out. Thus its frequency range is smaller than that of broad-
band white noise. This is also used in masking specific test 
frequency during pure tone audiometry. 
 
(c) Speech noise: All noises in speech range frequencies are called 
speech noise (300-3000 Hz). All the other frequencies are generally 
filtered out. 
 
Masking is a mechanism to produce inaudibility of one sound by the 
producing another. In clinical audiometry, one ear is occupied by a sound 
while the other ear is being tested. Masking of ear which is not tested is 
very essential in all forms of bone conduction tests, while in case of air 
conduction tests, it is required only when the difference of hearing 
between two ears exceeds more than 40 dB. 
In clinical audiometry, one ear is occupied by a sound while the other ear 
is being tested. Masking of ear which is not tested is very essential in all 
forms of bone conduction tests, while in case of air conduction tests, it is 
required only when the difference of hearing between two ears exceeds 
more than 40 dB. 
 
Wide range of human voices falls in this range. PTA is the average 
threshold measure of all three frequencies of hearing. This roughly equal 
to the speech reception threshold. 
 
Hearing level is the sound pressure level which is delivered by an 
audiometer at a respective frequency. It is measured in decibels. The 
reference is maintained at audiometric zero. If an audiometer produces a 
sound at 70dB, it is represented as 70dB HL. 
 
Physiology of hearing: 
Sound waves travel through external auditory meatus and produce 
vibrations in the tympanic membrane. Vibrations from tympanic 
membrane travel through malleus and incus and reach the stapes resulting 
in the movement of stapes. Movements of stapes produce vibrations in 
the fluid of cochlea. These vibrations stimulate the hair cells in the organ 
of Corti. This in turn, causes generation of action potential in the auditory 
nerve fibers. When auditory impulses reach the cerebral cortex, the 
perception of hearing occurs. Thus, during the process of hearing, ear 
converts enery of sound waves into action potentials in the auditory nerve 
fibers. This process is called sound transduction. 
 
Role of inner ear: 
Traveling wave: Movement of foot plate of stapes against oval 
window causes movement of perilymph in scala vestibuli. This fluid does 
not move all the way from oval window to round window through 
helicotrema. It immediately hits the vestibular membrane near oval 
window. This causes movement of fluid in scala media, since the 
vestibular membrane is flexible. This causes bulging of the basilar 
membrane towards scala tympani. This increases the elastic tension in 
basilar fibres in the portion of the basilar membrane. This tension initiates 
a wave,which travels along basilar membrane towards the helicotrema. 
 
Resonance point: It is a part of basilar membrane, which is 
activated by traveling wave. Initially each wave is weak. When it travels 
through the basilar membrane from base towards apex, the wave becomes 
stronger and at one point it becomes very strong and activates the basilar 
membrane. This resonance point of the basilar membrane immediately 
vibrates back and forth. The traveling wave stops here. Distance between 
stapes and resonance point is inversely propotional to frequency of sound 
waves reaching the ear. Wave generated by high pitched sound 
disappears near the base of the chochlea, medium-pitched sound reaches 
half of the way and wave generated by low pitched sounds travel the 
entire distance of the basilar membrane. 
 
Excitation of hair cells: 
Stereocilia of hair cells in organ of cortii are embedded in tectorial 
membrane. Haircells are tightly fixed by cuticular lamina reticularis and 
the pillar cells. When travelling wave causes vibration of basilar 
membrane at the resonance point, the basilar fiber, pillar cells, hair cells 
and lamina reticularis move as a single unit. It causes movements of 
stereocilia leading to excitement of hair cells and generation of receptor 
potential. 
 
Sound Transduction:  
It is type of sensory transduction in the hair cells in the organ of 
Corti by which sound energy is converted into action potentials in the 
auditory nerve fiber. Three  types of electrical events that occur during 
sound transduction are : 
(1) Receptor potential or chochlear microphonic potential 
(2) Endochochlear potential or endolymphatic potential 
(3) Action potential in auditory nerve fiber 
 
 
Role of hair cells: 
Inner hair cells and outer hair cells have different roles during sound 
transduction. The inner haircells are responsible for sound transduction, 
i.e. these receptor cells are the primary sensory cells, which causes the 
generation of action potential in auditory nerve fibers. Outer hair cells 
have a different action. These hair cells are shortened during 
depolarization and lengthened during hyperpolarisation. This process is 
called electromotility. This action of outer hair cells facilitates the 
movement of basilar membrane and increases the amplitude and the 
sharpness of sound. Hence, the outer hair cells are collectively called 
chochlear amplifier. 
 
Role of efferent nerve fibers of hair cells: 
They play an important role during sound transduction by releasing acetyl 
choline. Efferent nerve fiber to inner hair cell terminates on the 
auditory(afferent)  nerve fiber where it leaves the inner hair cell. It 
controls the generation of action potential in auditory nerve fibre by 
inhibiting the release of  glutamate from inner hair cells. 
 
Theories of hearing: 
(1) Telephone theory: It was postulated by Sir Rutherford in 1880. It 
is also called frequency theory. According to this theory, the 
chochlea plays a simple role of a telephone transmitter. In 
telephone, sound vibrations are converted into electrical impulses, 
which are transmitted by cables to the receiving end. Where 
electrical impulses are converted to sound waves. Similarly, 
chochlea converts sound waves into electrical impulses of same 
frequency. Impulses are transmitted by auditory nerve fibres to 
cerebral cortex, where perception and analysis of sound are done. It 
is approximated that, the nerve fibres can transmit maximum of 
thousand impulses per second. Thus,the telephone theory fails to 
explain the transmission of sound waves with frequency above 
1000 cycles per second. 
 
(2) Volley theory:  Wever postulated this theory in 1949. According 
to this theory, the impulses of sound waves with frequency above 
1000 cycles per second are transmitted by different group of nerve 
fibers. However there was no evidence to prove it. Thus not 
accepted by many. 
 
(3) Resonance theory of Helmholtz: This theory was proposed by 
Helmholtz in 1863. According to this theory analysis of sound 
frequency is the function of chochlea. Helmholtz named the basilar 
fibers as resonators and compared them with resonators of piano. 
When a string in piano is struck, sound with a particular note is 
produced. Similarly, when the sound with particular frequency is 
applied , the basilar fibes in a particular portion of the basilar 
membrane are stimulated.  
 
(4) Place theory: According to this theory, nerve fibers from different 
portions of organ of cortii on basilar membrane give response to 
sounds of different frequency. Accordingly, corresponding nerve 
fiber from organ of corti send information to the brain regarding 
the portion of organ of corti that is stimulated. Many evidences are 
present to support the place theory. E.g. If a person is exposed to 
loud noise of a particular frequency for a long period, he becomes 
deaf for that frequency. It is found that the specific portion of organ 
of corti is destroyed. 
 
(5) Traveling wave theory: This theory was derived from place 
theory. It explains the travelling wave generation in basilar 
membrane. 
 
Auditory Pathway: 
Hair cells in the organ of corti are the receptors of auditory sensation. All 
hair cells are innervated by afferent and efferent nerve fibers. The afferent 
cells forms the auditory pathway. First order neurons of auditory pathway 
are the bipolar cells of spiral ganglion. Their long processes leave the ear 
as cochlear nerve fibers and enter medulla oblongata, where they divide 
into dorsal and ventral cochlear nucleus on same side of medulla. 
 
         These act as second order neurons, where they run as different 
groups to cross the superior olivary nucleus, lateral lemniscus and 
recticular formation. The third order neurons are in the superior olivary 
nuclei and nucleus of lateral lemniscus. Fibers from medial geniculate 
body go the tremporal cortex, via the internal capsule as auditory 
radiation. Some fibers run to inferior colliculus which are responsible for 
reflex movements of head in response to auditory stimuli. The cortical 
auditory centers in the temporal lobe of cerebral cortex lie are the primary 
auditory area 41; 42 and Wernicke area. The secondary auditory                         
area is 22. 
 
  
Figure. 2. Auditory Pathway 
 
 
Hearing loss: 
Hearing loss can be of three types (i) Conductive hearing loss (ii) 
Sensorineural hearing loss (iii) Mixed hearing loss. While auditory 
function is being assessed it is important to find out the type of hearing 
loss; degree of hearing loss; site of lesion and cause of hearing loss. 
Hearing of an individual can be tested by clinical and audiometric tests. 
 
Sensorineural hearing loss: This results from cochlear lesions, VIII th 
nerve or central auditory pathways. It may be congenital or acquired. The 
characteristics of sensorineural hearing loss are: 
- A positive Rinne test 
- Weber lateralized to better ear 
- Bone conduction reduced on Schwabach and absolute bone 
conduction test. 
- Mostly high frequency loss 
- No gap between air and bone conduction curve on audiometry 
- Loss may exceed 60dB 
- Speech discrimination is poor 
- There is difficulty in hearing when noise is present 
 
 Table: 1:
 
 
 
 
 
 
CONDUCTIVE
SENSORY(COCHLEAR)
    Classification of hearing loss
HEARING LOSS
ORGANIC
SENSORINEURAL
NEURAL
PERIPHERAL (8TH 
NERVE)
CENTRAL (CENTRAL 
AUDITORY PATHWAY)
NON-ORGANIC
 
 
Congenital sensorineural hearing loss is present from birth and is the 
result of anomalies of the inner ear or damage to the hearing apparatus by 
prenatal or perinatal factors. 
 
Acquired sensorineural hearing loss appears later in life. The cause may 
be genetic or non- genetic. The genetic cause of hearing loss may 
presents late and damages only the hearing. It can even be a component 
of a larger syndrome with other the body systems being involved. 
Common causes of acquired sensorineural hearing loss are: 
 
- Infections of labyrinth 
- Trauma to labyrinth 
- Noise-induced hearing loss 
- Ototoxic drugs 
- Presbycusis 
- Menier’s disease 
- Acoustic neuroma 
- Sudden hearing loss 
- Systemic disorders like diabetes, hypothyroidsm, kidney disease 
and autoimmune disorders. 
 
 
 
Specific forms of hearing loss: 
 
A. Inflammation of the labrynth  
1. Viral labrynthitis : viruses usually reach the inner ear by blood 
stream affecting stria vascularis , endolymph and organ of corti. 
Measels,mumps and cytomegalovirus are known to cause 
labrynthitis. 
 
2. Bacterial : these infections reach the labrynth through the 
middle year or through CSF.sensory neural deafness following 
meningitis is a known complication . 
 
3. Bacteria can invade the labrynth along nerves , vessels, coclear 
aqueduct or endo lymphatic sac and this causes complete 
distruction of the membraneous labrynth. 
 
4. Syphilitic : sensory neural hearing loss is caused both by 
congenital and acquired syphilis . syphilitic involvement of the 
inner ear can cause sudden sensorineural hearing loss which 
may be unilateral or bilateral. Menier’s syndrome with episodic 
hearing loss, tinnitus and aural fullness. Tullio phenomenon 
where loud sounds produce vertigo. 
 
B. Familial Progressive Sensorineural hearing loss: It is genetic 
disorder characterized by progressive degeneration of cochlea. It 
may start late in childhood or in early adult life. 
C. Ototoxicity: Various chemicals and drugs affect the inner ear and 
produces sensorineural hearing loss and tinnitus. Symptoms of 
ototoxicity-hearing loss, tinnitus or giddiness may be noted during 
treatment or even after completion of entire treatment. 
Table 2 : The list of ototoxic drugs are 
OTOTOXIC  DRUGS 
 
  
A. Aminoglycoside antibiotics:                  E. Analgesics: 
 
-Streptomycin                                          - Ibuprofen 
- Tobramycin                                            - Salicylates  
- Gentamicin                                             - Indomethacin 
- Neomycin                                              - Phenyl butazone 
            - Amikacin                                                                                                                      
                                          F. Chemicals: 
B. Diuretics                                                 
                                                                   -Alcohol 
- Furosemide                                                - Tobacco 
- Ethacrynic acid                                         - Carbon monoxide poisoning 
                                                                              G. Miscellaneous: 
C. Antimalarials:       
                                                                  - Erythromycin 
- Quinine                                                     - Ampicillin 
- Chloroquine                                              - Propranolol 
 
D. Cytotoxic drugs: 
 
- Nitrogen mustard 
- Cisplatin 
- Carboplatin 
D. Noise trauma: 
 
Hearing loss due to exposure to noise exposure is known in boiler 
makers, iron smiths, copper smith and artillery men. Now a day’s 
noise trauma has become very significant as it has become an 
occupational hazard. Hearing loss caused by excessive noise can be 
divided into two groups: 
 
1. Acoustic trauma: Permanent damage to hearing can occur 
even on single brief exposure to very intense sound. E.g.: 
Gunfire; explosion. Sudden loud sounds damage cause damage 
to the outer hair cells disrupting the organ of corti and will 
result in rupture of the Reissner’s membrane. In some cases 
rupture of tympanic membrane and disruption of ossicular chain 
can happen in severe blast. 
 
2. Noise-induced hearing loss: Here hearing loss occurs 
following chronic exposure to less intense sounds. This is 
mostly noted as occupational hazard in people working in noisy 
environment. 
 
 
 
 
 
 
The damage caused by noise trauma depends on many factors like: 
a. Frequency of noise 
b. Intensity and duration of noise 
c. Continuous or interrupted noise 
d. Susceptibility of the individual 
e. Any pre-existing ear disease 
E. Sudden Hearing loss: It is a sensorineural hearing loss, that is 
developed over a period of hours or few days. Hearing loss may be 
partial or complete. It is mostly unilateral and may be accompanied 
by tinnitus or spells of vertigo. Mostly the cause of this sudden 
deafness remains unclear and termed as idiopathic. The three main 
aetiological factors generally considered are: viral, vascular or 
rupture of cochlear membrane. The other factors causing sudden 
hearing loss are: 
 
- Infections 
- Trauma 
- Vascular 
- Ear pathology like Meniere’s disease. 
- Toxic 
- Neoplastic 
- Psychogenic  
F. Presbycusis: Sensorineural haering loss associated with aging 
physiology in the ear is termed as presbycusis. Generally it 
manifests at 65 years or even earlier. The four pathological types 
are: 
- Sensory 
- Neural 
- Strial or metabolic 
- Cochlear conductive  
The tests for hearing are: 
A] Clinical tests of hearing are (i) Finger Friction Test (ii) Watch Test 
(iii) Speech Tests (iv) Tuning Fork Tests which include (a) Rinne test (b) 
Weber test (c) Absolute bone conduction test (d) Schwabach’s test (e) 
Bing test (f) Gelle’s test. 
Rinne tuning fork test: is formulated to find the difference between air 
conduction with that of bone conduction. In normal conditions, air 
conduction is more than bone conduction and the tuning fork will be 
heard loud in the opposite ear canal than when it is placed over the 
mastoid bone behind. 
 
The alternate method for doing this test is by threshold comparison 
method. In this method the activated tuning fork is held opposite the 
external canal till it is no longer heard. It is then placed over the mastoid 
process. If sound is heard once more, then it is considered that bone 
conduction is better than air conduction and the test is considered 
negative. The test when performed with 256 Hz tuning fork has greater 
sensitivity and specificity. The specificity of this test increases above 
30dB conductive deafness, decreases when narrow air-bone gap is found.  
False positivity of this test is about 20%. 
 
Weber tuning fork test: This test is used only if  asymmetrical or 
unilateral hearing is seen in patients. The basis of this is by placing a 
tuning fork in the centre of the skull being heard louder in the ear with a 
conductive impairment in case of sensorineural loss it is louder in the 
better ear. 
 
This difference can be distinctive only, if the examiner has done a clinical 
hearing test previously and if he knows which ear has better hearing. The 
test is done by keeping an activated tuning fork on the forehead or over 
the bridge of nose or on the incisor teeth. The tuning fork can also be 
placed over the vertex of the skull in the midline. Then the patient is 
asked to identify the ear in which the sound is heard or otherwise in 
which ear the sound is louder. If the sound is heard in the better hearing 
ear, then the poorer ear is considered to have sensorineural impairment. If 
it is heard in the affected ear, then it is considered as conductive 
impairment. This test has a low sensitivity and specificity. 
 
Absolute bone conduction test: Bone conduction is measurement of the 
function of cochlea. Here bone conduction of the patient is compared 
with the examiner, assuming the examiners have hearing within normal 
limits. The external auditory canal of both the examiner and the patient 
are closed, so that ambient noise entering through air conduction route is 
prevented. In case of conductive hearing loss, the subject and the 
examiner hears the tuning fork for equal time period. Whereas in case of 
sensorineural loss, the subject perceives the tuning fork for a brief period 
of time. 
 
Schwabach’s test: Here again the bone conduction of the patient is 
compared with the examiner, assuming that he has hearing within normal 
limits. But in this test, the meatus is not occluded. Schwabach’s test  is 
reduced in case of sensorineural deafness and lengthened in case of 
conductive deafness. 
 
The Bing test: it is done on the same basis of Weber test in which closing 
of the external auditory canal increases the tuning fork  sound in the ear 
to be tested, if conductive hearing loss is present. It is done by keeping a 
vibrating tuning fork over the mastoid process and the external auditory 
meatus is also occluded.  
 
If increase in sound is present then there is less likelihood that there is 
conductive hearing loss. However, if it remains the same, then it is more 
likely to be a conductive deafness. The specificity and sensitivity of this 
test is also very low. Most of the situations normal individuals are 
identified as conductive deafness. This test is not used widely. 
 
Tuning fork tests should generally be reserved for situations where 
audiometry is not satisfactory. The results must be interpreted keeping in 
mind the low sensitivity and specificity. 
 
B] Audiometric tests are (i) Pure tone audiometry (ii) Speech 
audiometry (iii) Bekesy audiometry (iv) Impedance audiometry. 
 
C] Special tests of hearing are (i) Recruitment (ii) Short increment 
sensitivity index (SISI) (iii) Threshold tone decay test (iv) Evoked 
response audiometry (v) Otoacoustic emissions (vi) Central auditory tests 
(vii) Hearing assessment in children and infants. 
 
Pure tone audiometry : Pure tones are produced by an electronic device 
called an audiometer. The intensity of these tones can be increased or 
decreased in steps of 5 dB.  Generally threshols for air conduction are 
calculated for tones of 125, 250, 500, 1000, 2000, 4000 and 8000 Hz and 
for thresholds of bone conduction, it is done at 250, 500, 1000, 2000 and 
4000 Hz.  
 
The measure of intensity of tones that  has to be increased more than the 
level of normal is considered as the degree of hearing impairment in that 
particular frequency. Audiogram is a graphical representation of the 
charted values. The bone conduction threshold is a measurement of 
function of cochlea. The variations in the air conduction and bone 
conduction thresholds (A-B gap) are a measurement of the degree of 
conductive hearing loss. It is observed that the calibration of audiometer 
is done in such a way that the perception in a normal person, both the air 
and bone conduction remains at zero dB and no A-B gap is noted. The 
turning fork test generally shows AC>BC. 
 
When the difference of hearing in the 2 ears is 40 dB or more in 
thresholds of air conduction then the ear with better hearing is masked so 
as to not to get a shadow curve in the better ear that is not being tested. In 
the same way masking is important in all studies of bone conduction. 
Masking is carried out by delivering a narrow-band noise to the ear that is 
not being tested. The benefits of pure tone audiogram are (i) It is a 
measurement threshold for hearing in both air and bone conduction, and 
also the type and degree of hearing loss. (ii) It is a reference for future 
record. (iii) Hearing aids can be prescribed only after an audiometery (iv) 
Speech reception thresholds can be predicted with its help (v) The degree 
of handicap can be assessed for medicolegal issuses. 
 
 
Figure. 3: Image showing patient undergoing Pure tone audiometry 
 
  
 Figure. 4. Audiogram 
 
Equipment: 
A pure tone audiometer is designed with a set of basic functions. The 
technical requirements for the instrument are specified by international 
standard, in which four types are identified based on complexity of 
functions and working range of various characteristics. 
 
 
  
                               
 
  
Pulse former Attenuator Amplifier 
Random 
noise 
generator 
Band-pass 
filter 
Attenuator Amplifier 
 
Bone vibrator 
Oscillator 
Earphon
Fig.4:  Flow diagram of pure tone audiometery 
speech audiometry is a test in which the patient’s capacity to hear and to 
understand speech is calculated. 2 parameters are taken into 
consideration: (i) Speech reception threshold (ii) The discrimination 
score. SRT is the intensity at which minimum words of 50% are 
reciprocated righttly by the patient. The headphones of an audiometer 
delivers a set of spondee words to both nears. 
An SRT more than pure tone average of 10dB suggests that hearing 
loss is of functional type. Discrimination score is also termed as speech 
recognition score. It is a measure of patient’s capacity to understand 
speech. Here phonetically balanced words are delivered to both ears at an 
intensity 30-40 dB above the SRT. 
 
Thus, speech audiometry helps (a) to differentiate an organic 
hearing from the functional one. (b) to indicate at which intensity the 
discrimination score is best, and this is useful for fitting apt hearing aid 
and setting its volume for optimal hearing and (c) to differentiate a 
cochlear from retrocochlear lesion. 
 
 
 
 
MANAGEMENT OF HEARING IMPAIRMENT: 
Management of individuals with hearing impairment can be determined 
by the degree of hearing impairment, whether the impairment is 
sensorineural, conductive or mixed. Ears with mild, moderate or severe 
impairment are given the option of hearing aids. Those with profound or 
total impairment, cochlear implants may be suggested. Middle ear 
implants were developed for those with conductive hearing loss but in 
long term it could be used for sensorineural hearing loss. 
 
All individuals with hearing impairment need some rehabilitation for 
communication. The various means of rehabilitation are: 
1. INSTRUMENTAL DEVICES 
HEARING AIDS COCHLEAR IMPLANTS ASSISTIVE DEVICES 
2. TRAINING 
SPEECH READING AUDITORY TRAINING SPEECH 
CONSERVATION 
Hearing aids: 
Hearing aids partially overcome the deficits associated with hearing loss. 
For a sensorineural hearing loss, there are several deficits to overcome. 
Some sounds are inaudible and some are heard because partial spectra are 
audible. 
Hearing aids are devices that amplify sound by electrical or chemical 
means. The basic components of a hearing aid are: 
 
- Microphone: They collect sounds and transform it into electrical 
energy. The microphones are generally magnetic in type. It consists 
of diaphragm that converts sound energy into mechanical energy. 
 
- Amplifier: The function is to increase the electrical voltage which 
is received from the microphone. An implanted transmitter in the 
amplifier increases the voltage. 
- Receiver: It transfers electrical energy back into sound waves with 
a much greater amplitude than those which fell upon the 
microphone. The receivers are both air conduction type as well as 
bone conduction type. These magnetic receivers have their 
diaphragm connected to a vibrator which is placed over the mastoid 
process. The vibrations are transmitted to the bony labyrinth and 
fluid in the cochlea. 
- Battery : They are placed in the device to supply power. 
Diabetes mellitus is characterized by chronic hyperglycemia with 
disturbances of carbohydrate, protein and fat metabolism resulting from 
defects in insulin secretion, insulin action, or both. The effects of diabetes 
mellitus include long term damage, dysfunction and failure of organs like 
eye, ears, heart, kidneys and blood vessels. It may present with symptoms 
like thirst, polyuria, polyphagia, blurring of vision and weight loss. And 
in more severe forms it may present as ketoacidosis or nonketotic 
hyperosmolarity, which in the absence of treatment leads to stupor, coma 
and death. 
A number of specific causes of diabetes mellitus have been 
identified, the etiology and pathogenesis is not clear. The majority of 
cases fall under two broad etiopathological categories, now called as type 
1 and type 2 diabetes. Recently the WHO along with expert committee of 
the American Diabetes Association (ADA) has given a new classification.   
 
 
 
 
 
Table 4: Etiological classification of disorders of glycemia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This classification differs considerably from the previous 
recommendation which classified using terms such as insulin-dependent 
diabetes and non-insulin dependent diabetes [4]. These terms were 
misused and classified patients based on treatment needs rather than 
etiologic characteristics. So the terms type 1 and type 2 diabetes have 
been adopted for the most common forms of diabetes mellitus. 
 
 
TYPE 1 
Beta cell destruction usually leading to absolute insulin deficiency 
A) Autoimmune 
B) Idiopathic 
TYPE 2 
A) Predominantly insulin resistance 
B) Predominantly insulin secretory defects 
OTHER SPECIFIC TYPES OF DIABETES 
A) Genetic defects of beta cell dysfunction 
B) Genetic defects in insulin action e.g: Type A insulin resistance 
C) Diseases of exocrine pancreas e.g: Fibro calculus pancreatopathy 
D) Endocrinopathies e.g: Acromegaly, cushings etc 
E) Drugs or chemical – induced e.g: Glucocorticoids 
F) Infections e.g: congenital rubella 
G)  Uncommon forms of immune-mediated diabetes e.g: Stiff Man Syndrome 
H) Other genetic syndromes 
GESTATIONAL DIABETES 
Clinical Stages: 
Individuals who develop diabetes pass through several clinical stages 
during the development. Initially, glucose regulation is normal and no 
abnormality of glycemia can be identified even if the individual 
undergoes oral glucose tolerance test. This stage is followed by a period 
of variable duration where in glucose regulation is impaired. Some 
amount of fasting glucose concentration may be noted or oral glucose test 
may show impairment. 
Once diabetes develops, glycemia may be controlled by lifestyle changes 
like diet and increased physical activity in some patients, whereas in 
others oral hypoglycemic agents or insulin  is needed for control or 
prevention against ketosis and ketoacidosis. 
 If insulin is required to prevent ketosis such patients are labeled as 
“insulin requiring for survival”. In all forms remission may be present. 
Patients may revert to having impaired glucose regulation or even normal 
glycemia, particularly if diabetes is of recent onset. This is seen most 
frequently in patients with recent-onset type 2 DM in whom lifestyle 
intervention or early aggressive treatment may result in apparent reversal 
of the abnormality with reversion to impaired or normal glucose    
tolerance [5].  
This may be seen in type 1 diabetes also, where in a short period of 
insulin treatment may result in a variable period when insulin is no longer 
required for survival and glucose tolerance may improve, the so called 
honeymoon period. Eventually these patients need insulin treatment for 
survival [6]. 
All subjects with diabetes can be classified according to clinical stages 
regardless of underlying etiology of diabetes. The stage of glycemia may 
change over time depending on the extent of underlying disease process.  
Impaired glucose regulation refers to the metabolic state intermediate 
between normal glucose homeostasis and diabetes that can be identified 
by impaired glucose tolerance or impaired fasting glucose [7]. They are 
not synonymous and represent different abnormalities of glucose 
regulation, even if they occur together. These patients are at a higher risk 
of progressing to diabetes. 
ETIOLOGIC TYPES  
Type 1 Diabetes Mellitus: It is a form of diabetes primarily due to β- cell 
destruction. This usually leads to a type of diabetes in which insulin is 
required for survival. These individuals are  metabolically normal before 
the disease is clinically manifested, but the process of β- cell destruction 
can be detected  earlier by the presence of certain antibodies like anti-
GAD, anti-islet cell or anti-insulin antibodies. Individuals with one or 
more of these antibodies can be  subclassified as type 1A, immune 
mediated type 1 diabetes. Type 1 diabetes can also occur in the absence 
of autoimmune antibodies and without evidence of any autoimmune 
disorders. It is a progressive form of disease with marked hyperglycemia 
resulting in insulin requirement for prevention of ketosis and survival. 
These individuals are classified as type 1B or idiopathic diabetes[8]. 
The rate of β- cell destruction is variable, being rapid in some individuals 
especially in infants and children, and slower in adults. Individuals 
become dependent on insulin for survival only many years after the 
detection of diabetes. Type 1 diabetes patients have low or undetectable 
levels of insulin and plasma C- peptide. These patients are more prone for 
ketoacidosis, although they have no clinical evidence of autoimmune 
antibodies. They may suffer from episodic ketoacidosis, but pathogenetic 
basis for this insulinopenia remains unclear. 
Type 2 Diabetes Mellitus: It is the most common form of diabetes. It is 
characterized by disorders of insulin action and insulin secretion. usually 
both are present at the time of clinical manifestation. 
 
 
 
  
 
 
Fig. 5: METABOLISM OF INSULIN PATHWAY 
 The specific etiology of this form of diabetes is yet unknown. Auto 
immune destruction of β- cell does not occur in this form of diabetes. 
Type 2 diabetes patients usually have insulin resistance rather than 
absolute insulin deficiency. These patients do not need insulin treatment 
for survival although many may require it for glycemic control. This form 
of diabetes is associated with progressive β- cell failure with increasing 
duration of diabetes [9]. Ketoacidosis rarely occurs by itself but 
conditions associated with stress and other illnesses such as infection can 
increase the risk 
Type-2 diabetes patients are mostly obese when they develop diabetes 
and obesity aggravates the insulin resistance.this form of diabetes goes 
undiagnosed for many years because the hyperglycemia develops 
gradually and in early stages it is not severe enough to produce the classic 
symptoms of diabetes.however these patients are at increased risk of 
developing macrovascular and microvascular complications.  
The circulating levels of insulin may be normal or elevated yet 
insufficient to control glucose levels in the blood within the normal range 
because of insulin resistance. Thus they have relative insulinopenia. 
Insulin resistance may improve with weight reduction or pharmacologic 
treatment and results in normalization of glycemia. Women with previous 
history of gestational diabetes and individuals with characteristics of 
insulin resistance syndrome like hypertension and dyslipidemia are at 
higher risk of developing type 2 diabetes. The risk also increases with 
age, obesity and physical inactivity. Lifestyle measures to reduce weight 
such as dietary regulation and increased physical activity reduce or delays 
the development of diabetes [10; 11]. 
Other Specific Types of Diabetes Mellitus 
Maturity-onset diabetes of the young (MODY): 
This subgroup includes a relatively rare monogenic disorder characterized 
by non–insulin dependent diabetes with autosomal dominant inheritance 
and the age of onset is 25 years or younger. Patients are not obese, and 
their hyperglycemia is due to impaired glucose-induced secretion of 
insulin. There are Six types of MODY which have been described. 
Except that in MODY 2, a glucokinase gene is defective, all other types 
involve mutations of a nuclear transcription factor that regulates islet 
gene expression. The enzyme glucokinase is a rate-limiting step in 
glycolysis and determines the rate of adenosine triphosphate (ATP) 
production from glucose and insulin secretion.  
 
 
MODY 2, due to glucokinase mutations, is usually mild, associated with 
only slight fasting hyperglycemia and few diabetic complications. It  
responds well to hygienic measures or low doses of oral hypoglycemic 
agents.  
 
MODY 3, is due to mutations in hepatic nuclear factor 1α and is the most 
common form. It accounts for two thirds of all MODY cases. The clinical 
course is of progressive beta cell failure and needs insulin for therapy. 
Mutations in both alleles of glucokinase present with more severe 
neonatal diabetes. 
 
Diabetes due to mutant insulin receptors: This is a rare subtype of type 
2 diabetes who are not obese. There are less than ten families being 
described in the past. Since affected individuals were heterozygous, 
diabetes presentation was mild, and appeared only in middle age. It also 
showed genetic autosomal dominant transmission. There is no evidence 
of clinical insulin resistance, and these patients respond well with 
standard therapy 
Defects in insulin receptor genes are found in more than 40 people with 
diabetes. These individuals have the highest insulin resistance associated 
with acanthosis nigricans. In very rare instances where the two receptor 
genes are abnormal , newborns present with leprechaun-like phenotype 
and do not survive through infancy. 
 
Wolfram syndrome: 
 
It is an autosomal recessive neurodegenerative disorder. It first becomes 
evident in childhood. It consists of diabetes insipidus, diabetes mellitus, 
optic atrophy, and deafness. This protein forms a part of the unfolding 
protein response and this protects the beta cells from endoplasmic 
reticulum stress and apoptosis during periods of high insulin demand. 
Diabetes mellitus along with optic atrophy presents in the first decade of 
life.  
 
 Sensorineural deafness and diabetes insipidus starts in the second decade 
of life in 60–70% of individuals . Ureterohydronephrosis, neurogenic 
bladder, peripheral neuropathy, cerebellar ataxia and psychiatric illness 
develops later in many patients. 
Fig 6: Acanthosis nigricans in the nape of the neck, with typical dark 
Fig 7: Acanthosis nigricans of the 
and velvety appearance 
 
axilla, with typical dark coloration 
and velvety texture 
 
 
Autosomal recessive syndromes: 
 
 In this form, there is homozygous mutations in a number of pancreatic 
transcription factors like  
NEUROG3, PTF1A, and GLI. It causes neonatal or childhood diabetes. 
Homozygous PTF1A 
mutations results in absent pancreas and cerebellar atrophy; NEUROG3 
mutations causes severe malabsorption and results in diabetes before 
puberty. Homozygous mutations in RFX6 causes the Mitchell-Riley 
syndrome. It is characterized by the absence of all islet cell types apart 
from pancreatic polypeptide cells, hypoplasia of the pancreas and 
gallbladder, and intestinal 
atresia. The gene EIF2AK3 helps in controlling the pathway for unfolding 
protein response. Absence of this leads to inadequate response to stress 
and accelerated beta cell apoptosis. Patients with mutation in this gene 
leads to neonatal diabetes, epiphyseal dysplasia, developmental delay, 
hepatic and renal dysfunction (Wolcott-Rallison syndrome). 
Diabetes mellitus secondary to other causes: 
 
 Glucose intolerance can be caused by endocrinr tumors secreting growth 
hormone like catecholamines, glucocorticoids, glucagon or somatostatins. 
In these incidences there is impairment  of peripheral responsiveness to 
insulin. With increase in levels of hormones hepatic output of glucose 
becomes a main causative factor. Catecholamines causes decrease in 
insulin release and becomes an added factor in producing carbohydrate 
intolerance, somatostatin inhibits insulin secretion and plays as a major 
factor. 
 
 Diabetes predominantly occurs in individuals with underlying defects in 
insulin secretion and hyperglycemia spontaneously resolves when the 
hormone excess is resolved. Extreme insulin resistance with acanthosis 
nigricans  is a rare syndrome which affects young woman with 
androgenic features and also in older woman who have circulating 
immunoglobulin binds to insulin receptors and this reduces the affinity to 
insulin. Many medications like calcineurin inhibitors, thiazides, β-
blockers, corticosteroids, niacin, atypical antipsychotics are known to 
produce carbohydrate intolerance or even frank diabetes. These 
medications act by either decreasing insulin secretion or by increasing 
insulin resistance or both.  Corticosteroids are known to increase insulin 
resistance  Thiazide diuretics and β-blockers moderately increase the risk 
for diabetes. Treating the hypokalemia produced by these thiazides may 
reverse the hyperglycemia. Atypical antipsychotics, olanzapine and 
clozapine, in 63articular have been associated with increased risk of 
glucose intolerance. These medications also causes weight gain and 
insulin resistance. An increase in rate of developing diabetic ketoacidosis 
has also been reported. 
DIAGNOSTIC CRITERIA FOR DIABETES: 
Patients having symptoms such as thirst, polyuria, unexplained weight 
loss, drowsiness or coma with marked glucosuria, the diagnosis of 
diabetes can be established by demonstrating fasting hyperglycemia. If 
the fasting glucose concentration lies in the diagnostic range for diabetes, 
an oral glucose tolerance test is not required for diagnosis. 
 A confirmatory test has to be performed because diagnosis of diabetes 
carries a considerable consequence for the patient. Intraindividual 
variation or incomplete fasting may result in wrong diagnosis. Whereas if 
the patient is asymptomatic or has minimal symptoms with fasting or 
plasma concentration values which are not diagnostic, an oral glucose 
tolerance test is required to confirm or exclude the diagnosis of diabetes. 
Normal glucose tolerance cannot be established on basis of fasting 
glucose determination alone. In normal healthy individuals, fasting 
glucose levels should be less than 100mg/dl in venous or capillary plasma 
and 90mg dl or less in whole blood. Individuals with fasting glucose 
levels above the characteristic value for normal healthy subjects but 
below diagnostic value of diabetes have a high likelihood of having either 
diabetes or impaired glucose tolerance. These levels represent a primary 
indication for an oral glucose tolerance test to confirm or exclude the 
diagnosis of diabetes. 
Table 5: Diagnostic Criteria 
Diagnostic Criteria for Diabetes Mellitus & Related Stages of 
Glycemia 
Glucose concentration, mg/dl 
 Capillary whole blood Venous Plasma 
Diabetes mellitus 
Fasting 
Or 
2-hour postglucose                      
 
        >=110 
 
>=200 
 
>=126 
 
>=200 
Impaired glucose 
tolerance 
Fasting 
Or 
2-hour postglucose 
 
<110 
 
140-199 
 
<126 
 
140-199 
Impaired fasting 
glycemia 
Fasting 
Or 
2-hour postglucose 
 
 
NA 
 
<140 
       
 
 
100-125 
 
<140 
NA – not applicable 
The 2- hour postglucose values are measured after a 75 gm oral glucose 
load 
 
 
 
 
Chronic complications of diabetes mellitus: 
 
Many organ  in the body are affected as a chronic complications of 
diabetes and it acts as the major cause for morbidity and mortality . There 
are tow types of complications - vascular and nonvascular . The vascular 
complications can be again subdivided into microvascular and 
macrovascular complications.  
 
Non vascular complications include conditions such as gastroparesis, 
infections, and skin changes. Long standing diabetes may be associated 
with hearing loss. Among metabolic disorders of glucose diabetis mellitus 
is most  commonly associated with auditory disfunction[12] 
 
Damage to the nerves and vessels of the inner ear are noted in many 
Histopathological studies in patients with diabetes. Neuronal degeneration in 
the auditory system was linked to these vascular changes as an important 
causative factor. The organ of corti cells which are important structures of 
hearing are complex components and its arrangement makes it also a potential 
target for hyperglycaemic damage. Such damage to any part of hearing 
mechanism can lead to hearing loss. 
 
 
  
 
  
Chronic complications of Diabetes Mellitus 
 
Microvascular complications 
Eye disease 
- Retinopathy 
- Macular edema 
Neuropathy 
- Sensory and motor (mono- and polyneuropathy) 
- Autonomic 
Nephropathy 
 
Macrovascular complications 
Coronary artery disease 
Peripheral arterial disease 
Cerebrovascular disease 
 
Others 
Gastrointestinal (gastroparesis, diarrhea) 
Genitourinary ( uropathy/ sexual dysfunction) 
Dermatologic 
Infections 
Cataracts 
Hearing loss 
Glaucoma 
Periodontal disease 
The risk of chronic complications increases as duration and degree of 
hyperglycemia increases. These complications do not become apparent 
till the second decade of hyperglycemia. As the type 2 diabetic patients 
have a long asymptomatic period of hyperglycemia, they may present 
with complications when diagnosis is made. The microvascular changes 
in both type 1 and type 2 diabetes are due to chronic hyperglycemia. 
Clinical trials prove that reduction in chronic hyperglycemia prevents or 
delays retinopathy, nephropathy and neuropathy. 
Evidence to prove that chronic hyperglycemia is a cause for developing 
macrovascular changes is less provided. However complications like 
coronary heart disease and mortality rates are 2 to 4 folds greater in type 
2 diabetes. These complications correlate with fasting and postprandial 
plasma glucose levels asa well as with HbA1C values.  Other factors like 
dyslipidemia and hypertension play an important role in macrovascular 
complications. 
Mechanisms of complications: 
Chronic hyperglycemia is a well known etiologic factor leading to 
complications of diabetes, the actual mechanism by which it leads to such 
diverse cellular and organ dysfunction is not clear. There are few 
prominent theories that have been enumerated to explain how 
hyperglycemia may lead  to chronic complications of diabetes. 
One theory states that raise in levels of intracellular glucose leads to the 
production of advanced glycosylation end products, which bind to a cell 
surface receptor via the nonenzymatic glycosylation of intra and 
extracellular proteins. The interaction of glucose with amino groups on 
proteins results due to nonenzymatic glycosylation . The AGEs are 
known to cross –link proteins, accelerate atherosclerosis, promotes 
glomerular dysfunction, reduces nitric oxide synthesis, induces 
endothelial dysfunction and leads to alteration of extracellular matrix 
composition and structure. Serum levels of AGEs correlates with the 
levels of glycemia, and these products accumulate as the glomerular 
filtration rate declines. 
Second theory is proposed on basis of observation that hyperglycemia 
increases glucose metabolism by sorbitol pathway. Increased levels of 
sorbitol concentration alters redox potential, increases cellular osmolality 
leading to generation of oxygen species which is reactive and further 
leads to other cellular dysfunction. Trails based on this theory have lead 
into clinical clues on complications like retinopathy, neuropathy and 
nephropathy. 
Third hypothesis suggests that the formation of diacylglycerol leading to 
activation of protein kinase C increases in hyperglycemia. This enzyme 
alters the transcription of genes for fibronectin, contractile protients, type 
IV collagen and extracellular matrix proteins. 
Growth factors play an important role in diabetes related complications. 
Vascular endothelial growth factor (VEGF-A) is found to be increased 
locally in diabetic retinopathy. Other enzymes that play an important role 
in diabetes related complication are epidermal growth factor, platelet- 
derived growth factor, insulin-like growth factor, growth hormones and 
even insulin. Even though hyperglycemia acts as the initial trigger factor 
for complications of diabetes, it is still unclear if the same 
pathophysiologic process is effective in all organs. 
Overall principles of long- term treatment: 
The main goals of therapy for both type 1 and type 2 are 
i) Eliminate the symptoms related to hyperglycemia 
ii) Reduce or eliminate the long-term microvascular and 
macrovascular complications of diabetes 
iii) Allow the patient to achieve a normal life as possible.  
In order to achieve these goals the physician should identify a target level 
of glycemic control for each patient, provide the patient with educational 
and pharmacologic resources necessary to reach the level, and monitor or 
treat the diabetes related complications. Symptoms of diabetes generally 
resolve when the plasma glucose is < 200mg/dl. 
The care of a diabetic individual requires a multidisciplinary team. Thus 
the term comprehensive diabetes care is used to emphasize the fact that 
optimal diabetes therapy involves more than plasma glucose 
management. Even though glycemic control is the central to optimal 
diabetes therapy, comprehensive diabetic care is needed to detect and 
manage diabetes specific complications and modify of developing 
diabetes associated diseases.  
Treatment Regimens 
 
A] Diet: 
 
 The fundamental element of therapy is a well-balanced, nutritious diet. 
The American Diabetes Association (ADA) recommendations states that 
about 45–65% of total daily calories should be in the form of 
carbohydrates; fat should be 25–35%  and proteins about 10–35% . In 
type 2 diabetes patients the intake of carbohydrate should be limited and 
it should be substituted by some other calories containing 
monounsaturated fats, like olive oil or oils in nuts which  can lower the 
levels of triglyceride and increase the level of HDL cholesterol. In obese 
individuals with type 2 diabetes, weight reduction by caloric restriction is 
an important goal of the diet. 300mg of cholesterol is the recommended 
level for both the types of diabetes.  
 
Medications for Treating Hyperglycemia: 
 
The medications for treating type 2 diabetes come under various 
categories: (1) Medications that primarily stimulate insulin secretion by 
attaching to the sulfonylurea receptor like Sulfonylureas, which remains 
as the most widely prescribed medications for treating hyperglycemia. 
 (2) Medications that primarily lower glucose levels by acting upon  the 
liver, muscle, and adipose tissue like metformin which acts on the liver, 
thiazolidinediones which act mostly on skeletal muscles and adipose 
tissue. (3) Medications that principally affect absorption of glucose like 
α-glucosidase inhibitors  acarbose and miglitol which are currently 
available for therapy. 
 (4) Medications that mimic incretin effect or prolong incretin action: 
Glucagon-like peptide 1 (GLP1) receptor agonists and DPP 1V inhibitors 
fall into this category. (5) Other: include Pramlintide that lowers glucose 
by suppressing glucagon and Slowing gastric emptying. 
 
 Sulfonylureas: 
 
  
The main action of the sulfonylureas is to initiate the release of insulin 
from β- cells of pancreas. There are specific receptors on the pancreatic 
β- cells surface which bind sulfonylureas in the order of  insulinotropic 
potencity. It has been observed these receptors closes the  potassium 
channels leading to depolarization of the  β cell when they are activated. 
This depolarized state allows calcium to enter into the cell and this 
promotes the release of insulin. 
 
 Sulfonylureas are not recommended for use in type 1 diabetic individuals 
as they require functioning  β cells in pancreas to deliver their effect on 
blood glucose. These medications are used in type 2 diabetes patients 
who show improvement during acute administration. This results in 
improvement in early phase of release of insulin which serves as 
refractory agent in acute glucose stimulation. It is metabolized in the 
liver. 
 
The metabolites are excreted by the kidney and, in the case of the 
secondgeneration sulfonylureas, partly excreted in the bile. Sulfonylureas 
are generally contraindicated in patients with severe liver or kidney 
impairment.  
 
Metformin: 
 
This is used alone or along with other oral hypoglycemic agents or 
insulin, in the treatment of  type 2 diabetes patients. Metformin activates 
adenosine monophosphate-activated protein kinase (AMPK) by 
uncoupling mitochondrial oxidative phosphorylation and increasing 
cellular AMP levels. Metformin’s therapeutic effects primarily derive 
from the increasing hepatic AMPK activity, which reduces hepatic 
gluconeogenesis and lipogenesis. Metformin is a substrate for organic 
cation transporter 1, which is abundantly expressed in hepatocytes and in 
the gut. 1.5–3 hours is the half life of metformin. It does not bind to 
plasma proteins. It is excreted unchanged by the kidneys as it cannot be 
metabolized in humans. Metformin is the first-line therapy for patients 
with type 2 diabetes. 
 
 The current recommendation is to start this medication at diagnosis. An 
added benefit of metformin treatment is that has propensity to maintain 
both fasting and postprandial hyperglycemia and hypertriglyceridemia in 
obese patients with diabetics without the complication of weight gain 
which is a known complication in treatment with insulin or sulfonylurea. 
Metformin is not effective in patients type 1 diabetes patients. Patients 
with chronic kidney disease should not be given this medication because 
failure to excrete it would produce high blood and tissue levels of 
metformin that could stimulate lactic acid overproduction. Also patients 
with liver failure or persons who abuse alcohol should not receive this 
medication because it could result in lactic acidosis. 
 
 500 mg, 850 mg, and 1000 mg tablets are the available doses of 
metformin.  500 mg and 750 mg doses are available as extended-release 
formulations. Even though the maximum dose is 2.55 gm, very less 
benefit is observed in doses more than 2000 mg. It is necessary to start 
with lower doses and then to increase the dosage very slowly in divided 
doses which is taken with meals so as to reduce the minor complications 
like gastrointestinal upsets.   
 
The frequent side effects of metformin are gastrointestinal symptoms like 
anorexia, nausea, vomiting, abdominal discomfort, diarrhea which occur 
in up to 20% of patients. These effects are dose related, tend to occur at 
onset of therapy, and often are transient side effects. Hypoglycemia does 
not manifest with treatment of metformin, so it permits to maintain an 
“euglycemic” state. So it is termed as “antihyperglycemic” medication. 
 
 Certain individuals receiving radiocontrast agents may manifest with 
acute kidney failure as a rare complication. Therefore it is recommended 
to with hold therapy with Metformin temporarily on the day of 
radiocontrast administration and it should be restarted a day or two later 
after confirmation that renal function has not deteriorated. 
 
 
 
Thiazolidinediones: 
 
Medications in this class of antihyperglycemic agents sensitize insulin in 
peripheral tissues. They bind a nuclear receptor called peroxisome 
proliferator-activated receptor gamma (PPAR-) and affect the 
expression of a number of genes. Observed effects of thiazolidinediones 
include increased glucose transporter expression, decreased free fatty acid 
levels, decreased hepatic glucose output, increased adiponectin and 
decreased release of resistin from adipocytes, and increased 
differentiation of preadipocytes into adipocytes. 
 
 It is also proven to reduce the levels of plasminogen activator inhibitor 
type 1, C-reactive protein matrix metalloproteinase 9 and interleukin 6. 
This class of medications does not cause hypoglycemia. The two drugs 
available for therapeutic use are Rosiglitazone and pioglitazone. They can 
be as monotherapy as well as  in combination with sulfonylureas; 
metformin or insulin, for lowering levels of  HbA1c. In instances where a 
combination is used, the dosage of insulin can be reduced by 30-50% and 
slowly insulin can be stopped.   
 
The dosage of rosiglitazone is 4–8 mg daily and of pioglitazone, 15–45 
mg daily, and the medication need not be taken with food. When 
thiazolidinedione and metformin are togeather  
the advantage hypoglycemia can be avoided. Patients who do not get 
adequate blood sugar control with sulfonylureas, generally maintain well 
with combination  
Insulin 
 
Insulin is indicated for type 1 diabetes as well as for type 2 diabetic 
patients with insulinopenia whose hyperglycemia do not respond to diet 
therapy alone or combined with other hypoglycemic medications. With 
the development of highly purified human insulin preparations, 
immunogenicity has been reduced markedly, thereby decreasing the 
incidence of therapeutic complications such as insulin allergy, immune 
insulin resistance, and localized lipoatrophy at the injection site.  
 
It has been impossible to replicate the patterns of secretion of intraportal 
insulin with short-acting or longer-acting insulin preparations given as 
subcutaneous injections. Even if  correction in diet and exercise are done 
routinely, along with capillary blood glucose level monitoring at home, 
control in blood glucose levels is possible only on using many mixtures 
of insulin at least two times a daily or a portable infusion pumps should 
be used. 
 
 Characteristics of available insulin preparations: 
 
Commercially available preparations of  insulin vary in terms of onset of 
time their biologic duration of action: 
A. Species of insulin: Recombinant DNA techniques are used to produce 
human insulin, which is widely available in the trade name of Novolin. It 
is marketed as either regular or NPH formulations. 
 
 Human insulin are available in five analogs, out of which three are 
rapidly acting, example insulin lispro, insulin glulisine and insulin aspart 
and two are long-acting example insulin glargine and insulin detemir. The 
FDA has given approval for clinical use of these drugs. Insulin derived 
from animal source is not used anymore in the United States. 
 
B. Purity of insulin: “Purified” insulin is the one which has proinsulin 
contamination < 10 ppm and is the degree of purity. The same is 
recommended by FDA. Now a day’s all available insulin forms contain < 
10 ppm of proinsulin and are termed as “purified”. These forms of 
insulins preserve their potency well, making refrigeration not very 
crucial. This property makes it easy to carry reserve supplies of insulin 
during traveling without losing its potency, but it has to be protected from 
direct heat or cold. 
C. Concentration of insulin: Currently in the United States, the available 
concentrations of insulin are 100 units/mL and it is dispensed as 10-ml 
vials. The low-dose (0.5- or 0.3-mL) disposable insulin syringes are now 
very popular. Doses as low as, 1–2 units can be measured accurately. 
U500 regular human insulin (Humulin R) is available in rare insistences 
where there is severe insulin resistance 
Methods of insulin administration: 
 
A. Insulin syringes and needles: Disposable plastic syringes in sizes 
1 ml, 0.5 ml, and 0.3 ml are available. The 0.3 ml low dose 
syringes have gained popularity now a day’s as majority of diabetic 
patients take less than 30 units of insulin as a single injection 
except in conditions like extreme insulin resistance which is a rare 
entity. Needles are available in 2 lengths, short are 8 mm and long 
is 12.7 mm. Long needles are used in patients who are obese to 
decrease the variability in absorption of insulin. These needles are 
ultrafine and size is small about 31 gauges, so pain of injection is 
much reduced. Disposable syringes can be used upto three to five 
times till the blunting of the needle is noted. Sterility can be 
maintained by recapping syringes between uses, to avoid infection 
with reuse. 
Needle cleansing with alcohol is avoided as it can dissolve the coating of 
silicon which may increase the pain while puncturing the skin. Any body 
part which is covered by loose skin,  like abdomen, upper arms, flanks, 
thighs, and upper buttocks can be chosen. Skin preparation with alcohol 
is no longer recommended required before injection as far as the skin is 
kept clean continues to be recommended To avoid delayed absorption 
rotation of sites is recommended as it causes fibrosis or lipohypertrophy 
due to repeated injections. However variability in absorption rates are 
noted in different sites. Subcutaneous injections are preferred to be given 
in the abdomen as regular insulin is found to absorb more rapidly.  In 
analog type insulin preparations the effect of anatomic regions appear to 
be much less 
 
A. Insulin pen injector devices: The need for carrying insulin vials 
and syringes are eliminated since the advent of insulin pens. 
Cartridges of insulin lispro, insulin aspart, and insulin glargine are 
available as reusable pens. Disposable prefilled pens are also 
available for insulin lispro, insulin aspart, insulin glulisine, insulin 
detemir, insulin glargine. Thirty-one gauge needles (5, 6, and 8 mm 
long) for these pens make injections almost painless. 
 
B.  Insulin pumps: Medtronic Mini- Med, Animas, Insulet, and 
Roche are some of the companies that make insulin infusion pumps 
for subcutaneous delivery of insulin. These pumps are small and 
are very easy to program. They offer many features, including the 
ability to set a number of different basal rates throughout the 24 
hours and to adjust the time over which bolus doses are given. 
They also detect pressure build-up if the catheter is kinked. 
Improvements have also been made in the infusion sets. The 
catheter connecting the insulin reservoir to the subcutaneous 
cannula can be disconnected, allowing the patient to remove the 
pump temporarily. Ominpod is an insulin infusion system in which 
the insulin reservoir and infusion set are integrated into one unit so 
there is no catheter. The pod, placed on the skin, delivers 
subcutaneous basal and bolus insulin based on wirelessly 
transmitted instructions from a personal digital assistant.  The 
advantage of continuous subcutaneous insulin infusion (CSII) is 
that it allows establishment of a basal profile tailored to the patient. 
The patient therefore is able to eat with less regard to timing 
because the basal insulin infusion should maintain constant blood 
glucose between meals. Also the ability to adjust the basal insulin 
infusion makes it easier for the patient to manage glycemic 
excursions that occur with exercise.  
The pumps also have software that can assist the patient to calculate 
boluses based on glucose reading and carbohydrates to be consumed. 
They can keep track of the time elapsed since last insulin bolus and the 
patient is reminded of this when he or she attempts to give additional 
correction bolus before the effect of the previous bolus has worn off. This 
feature reduces the risk of overcorrecting and subsequent hypoglycemia. 
 
RATIONALE FOR STUDY 
 
Our institution, PSG Institute of Medical Science & Research in 
Coimbatore serves as a referral centre for the southern states of India like 
Tamil Nadu, Kerala and Andhra Pradesh which have an agricultural 
economy. The modern lifestyle modification has led to many problems 
like obesity, early onset diabetes, dyslipidemia, coronary artery disease. 
Among these diabetes mellitus is found to be on the rise. This multi- 
system abnormality causes many irreversible changes in the body leading 
to many complications including hearing loss which is given less 
importance or neglected in many situations. 
 
Reviewing the available literature we realized that all important studies 
on prevalence of hearing loss among diabetic patients were done in the 
Europe and American Continents. But the incidence of diabetes mellitus 
and its complications in India has been steadily increasing. There is a lack 
of recognition of hearing loss as a complication of diabetes. It is this lack 
of awareness  and need for screening of these individuals at higher risk of 
developing hearing loss, that prompted us to undertake this study.   
 
 
 
MATERIALS & METHODS 
This is a cross-sectional study in which evaluation of 200 patients who 
were diagnosed with diabetes mellitus undergoing treatment on Out–
Patient or In-Patient basis in department of E.N.T and Endocrinology, in 
PSG Institute of Medical Science & Research, Coimbatore, Tamil Nadu 
from July 2012 to July2014 were considered.     
History of every patient was taken in detail and importance was given on 
their presenting complaints. Any significant past history of ear discharge, 
hearing loss or previous ear surgeries were elicited. History of duration of 
diabetes and mode of treatment were given importance. 
All the patients were taken up for Otoscopic examination, in which the 
ear canal and status of tympanic membrane were assessed.  
Inclusion Criteria for cases considered in the study: 
1. Known cases of Diabetes mellitus 
2. Age-group >30 years to <60 years 
3. Both genders 
 
 
 
 
Exclusion Criteria for cases: 
1. Individuals involved in occupations exposing to loud noise 
2. Individuals with previous history of ear discharge/hearing 
loss/tinnitus/ear surgery 
3. Otoscopic examination showing any ear pathology like wax, 
discharge, retracted tympanic membrane, perforated tympanic 
membrane or tympanosclerosis. 
4. Patients unwilling to comply with the study. 
 
Evaluation: 
All 200 patients were worked up with a Pure tone audiomertry. The 
audiogram was analyzed for hearing loss and if present it will be 
classified according to WHO classification. 
 
Pure tone audiometery: 
Pure Tone Audiometry is an audiometric evaluation which is done 
routinely. The results of which are charted in the form of audiogram 
which is used to describe the degree of hearing loss. In our study 
audiological examination was carried out in a sound proof room using the 
Pure Tone Audiometer model GSI 61 in the ENT department, PSG 
Institute of Medical sciences & research. To test the air conduction ear 
phones were used and a small vibrator, was used to test hearing by bone 
conduction which was placed over the mastoids. The signals presented to 
the subject by the audiometer were all characterized by The sound 
pressure level, frequency and wave form were all delivered at controlled 
rates to the subjects which was presented in the form of signals by the 
audiometer. 
The entire purpose and procedure of the test was explained in detail to the 
patients. On daily basis before starting the procedure biological 
calibration was done for both air and bone conduction. 
Pure Tone Audiometery: Air Conduction Threshold 
 Here a range of specific puretones are delivered to the patient through 
earphones and threshold for hearing is measured. Hughson – Westlake 
method is followed which is an ascending order. 
up 5, down 10 method is done 
Test frequencies 
An electronic device that delivers pure tones is called as an audiometer. 
The intensity of these tones can be either increased or decreased in steps 
of 5-db. The thresholds that are measured for air conduction are 250, 500, 
1000, 2000, 4000 6000 and 8000 Hertz. The thresholds for bone 
conduction are measured for 250, 500, 1000, 2000, 4000 Hz. The patient 
was briefed that tones of short duration would be heard in either the left 
or the right ear and these sounds to begin with are very faint. It was also 
explained that response for these sounds should be in the form of raising 
his finger incorrespondance to the side of the ear, as in which the tone 
was heard. The hand should be kept raised as long as it is heard, even if 
faint tone was heard. 
 Threshold determination:  
The test is started at 1000 Hz. A clearly audible signal, about 40 dB HL 
will be presented to the individual assuming that the hearing threshold of 
the subject is within normal limits. If the patient finds it difficult to hear 
then it is raised to 60 dB HL. The tone levels will then be reduced in 10 
dB steps till the tone became inaudible and the patient is not responsive. 
Next the level of tones will be raised in 5 dB steps, delivering one pulse 
in each level until obtaining a response. The point at which the individual 
makes a response on raising it by 5 dB will be considered as the 
threshold. The same test will be done at the higher frequency till 8000 
Hz. Again the threshold is brought back to 1000 Hz and then further 
lowered to 500 Hz and 250Hz to be tested. Then the opposite ear will be 
tested in a similar fashion. 
 
Pure Tone Audiometry: Bone Conduction Threshold  Bone conduction in 
pure tone audiometry is performed in combination with air conduction 
audiometry. This provides information about the elements of conduction 
in hearing loss. In this test hearing thresholds are measured for pure tones 
which are delivered with the help of a bone vibrator placed over the 
mastoid process behind the ear. The measurement was done by Hughson 
Westlake ascending up 5, down 10 method. 
Procedure: 
Thresholds like 250, 500, 1000, 2000, 4000Hz are measured for bone 
conduction. The patient was briefed that he would hear short tones that 
may be very faint and it might be simultaneously heard in any one ear or 
both ears . The response to this is done by lifting the finger corresponding 
ear in which he hears, as soon as he perceives the tone. He was also 
briefed about the bone vibrator placed over the mastoid which not 
supposed to be manipulated after it is placed finally. 
Threshold determination: 
In this test, the better ear is tested first, once the side difference is found 
out by prior testing or by Weber's test to determine the side of 
lateralization. The mastoid process is selected for the placement of bone 
vibrator. Initially test is done at 1000 Hz. An audible tone which is clear 
and  continuous is delivered and continous adjustments on the bone 
vibrator are done till the patient denotes that it is the loudest tone. It was 
made sure to avoid contact  between the vibrator and the outer ear. In this 
test earphones are not provided.  At about 40 dB test tones will be 
delivered for 1to 2 seconds and if it is at inaudible levels then, test tone 
will be increased in 10 dB steps until a response was noted. This is again 
repeated but by reduceing the levels 20 dB steps, until it becomes 
inaudible and no response was obtained from the patient. This is followed 
by raising levels in 5 dB steps, till the patient responds. The threshold 
level at which the patient responds is taken into consideration. The other 
test frequencies are also test as the test continues. The other ear is also 
tested. Masked pure tone audiometry has to be done if the difference of 
more than 40 dB between air conduction threshold of the test ear and the 
bone conduction threshold of the opposite ear or when the air bone gap of 
the poorer ear is more than 10 dB.  
 
  
RESULTS 
 
In this study, analysis of 200 patients diagnosed with diabetes mellitus 
was done in the Department of E.N.T, PSG Institute of Medical Sciences 
& Research from July 2012 to July 2014 to determine the incidence of 
hearing loss as a complication of diabetes mellitus. Detailed evaluation of 
each case was done comprising of the history, clinical examination 
including otoscopic examination with otoscope and pure tone audiometry. 
The clinical data was collected by means of a proforma and the 
observations from the audiogram were analyzed with the Master chart as 
shown in the Annexure. 
The results have been evaluated primarily keeping in mind the aim of the 
study, to determin the prevalence of Hearing loss and its association with 
Diabetes and to assess the hearing loss in diabetics and correlate it with 
age and duration of  diabetes  
In our study of 200 diabetic patients, 110 (55%) cases turned out to have 
sensorineural hearing loss. 
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In our study, the incidence of patients with diabetes mellitus amongst 
males was 56% (113 males) and 44% in females (87 females)
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In our study, maximum number of diabetic patients with hearing loss was 
noted among 51-60 years which was 99 cases, followed by 41
(68 cases) and only 33 cases among less than 40 years of age.
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From the above mentioned table, it is noted that the incidence of hearing 
loss was found to be more among patients 
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It is noted that in the right ear 95 cases had normal 
mild hearing loss, 15 had moderate and 3 cases had moderately severe 
and severe hearing loss respectively.
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It is noted that in the left ear, 92 cases had normal hearing, 81 had 
minimal hearing loss, 16 had moderate loss 
severe and 1 with profound hearing loss.
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From the above mentioned table, it is noted that maximum of
cases had hearing loss among the group 3
(25%) cases had mild hearing loss;
loss and 3 cases (2%) had moderately severe loss
group where 31 cases (16%) had hearing loss.
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Severity of hearing loss in left ear with duration of diabetes mellitus:
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From the above mentioned table, it is noted that, maximum of 59 (30%) 
cases had hearing loss among the group 3
(22%) cases had mild
loss and 5 cases (3%) had moderately severe loss, followed by 5
group where 32 cases (17%) had hearing loss.
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In our study it is noted that maximum incidence of 
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- 5 years duration. The p-
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1 6 
1 25 
 
 value is <0.01, 
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Overall severity of hearing loss in our study:
Hearing Loss 
Mild 
Moderate 
Moderate Severe 
Severe 
Profound 
Total 
 
In our study, it is noted that 72% of individuals with diabetes
sensorineural hearing loss, followed by 20% with moderate 
hearing loss. 
Moderate
20%
Moderate Severe
 
Hearing Loss [n=110] 
n (%) 
79 72% 
22 20% 
4 4% 
4 4% 
1 1% 
110 100% 
Mild
72%
3%
Severe
4%
Profound
1%
Hearing Loss [n=110]
  
  
  
  
  
  
  
 
 have mild 
sensorineural 
Overall incidence of hearing in our 
  
  
No. of patients 
Percentage 
 
  
From the above mentioned table, it is shown that, in our study 55% of 
diabetic patients were found to have sensorineural hearing loss and 45% 
of cases had hearing within normal limits.
Minimal
55%
study: 
Hearing Loss
Normal       
          Hearing 
loss 
90 110 
45% 55% 
 
Hearing Loss [N=200]
 
  
  
  
 
Normal
45%
DISCUSSION 
 
Hearing loss is a dysfunction of hearing and it varies in severity ranging 
from mild; moderate; severe or profound. Hearing loss in general can be 
divided into conductive type, sensorineural type or mixed type. The 
hearing impairment typically seen among diabetic patients is 
sensorineural type and bilateral. Diabetes mellitus has been proven an 
individual causative factor in developing sensorineural type of hearing 
loss [14]. 
 
Diabetic patients are found to have different types of hearing loss. One 
among them is gradually progressive and bilateral sensorineural type, 
mainly effecting high frequencies in elderly patients. This may be as 
same as presbyacusis, but with a loss more severe than expected because 
of aging [15]. 
 
Acquired hearing loss is defined as a loss of hearing function due to some 
nongenetic causes, for example triggered by environmental agents like 
chemicals, drugs and noise. Presbycusis or age- related hearing loss may 
have both a genetic and an acquired component. 
 
Sensorineural hearing loss results from lesions of cochlea, VIIIth nerve or 
central auditory pathway. Characteristically these patients have poor 
speech discrimination and difficulty in hearing in the presence of noise. 
The pathway for sound impulses from hair cells to inner ear to the 
auditory nerve and the brain is damaged It may be acute (sudden) or 
chronic sensorineural hearing loss.  
Common causes of acquired sensorineural hearing loss are: 
- Age related hearing loss 
-  Acoustic trauma 
-  Viral infections of the inner ear 
-  Meniere’s disease 
-  Drugs like aspirin, quinine, and aminoglycoside antibiotics, which 
can affect the hair cells 
- Neural deafness may be due to multiple sclerosis, brain tumor and 
stroke. 
-  Systemic causes like diabetes, hypothyroidism, artherosclerosis 
 
 
AGE:  
Our study has studied the pattern of hearing loss in diabetic patients and 
their effect of hyperglycemia on hearing thresholds and it shows 55% 
incidence of deafness. And the peak age group being affected with 
hearing loss in our study was between 50- 53 years of age.  
 
In contrast a study conducted by  Rajendran S , Anandhalakshmi et al[16] 
showed maximum incidence between 40- 50 years of age. On further 
review, we realize that acquired on set sensorineeural hearing loss can 
occur early in diabetic patients. Usually age related sensorineural 
deafness is more common in people more than 60 years of age. But here 
it is seen that diabetic patients are at higher risk of developing this 
sensory loss at a much younger age groups. 
 
It is also noted that in our study there were more people with diabetes 
among the age group 51-60 years of age (50%).The p value is <0.05, 
which makes it statistically significant. 
 
Sex: 
In our study it was noted that more number of diabetic males were 
affected with hearing loss, than females. In contrast Taylor and Irwin 
(1978) noted that diabetics who are females had a significantly higher 
hearing loss on comparing with diabetic male patients. 
But according to Cullen and Cinnamond (1993) [17] diabetic male 
patients had hearing worse than diabetic female patients  
 
From our study, we conclude that sex of an individual is not statistically 
significant (p>0.05) parameter in considering the susceptibility to develop 
hearing loss. 
 
It was also noted that out study of 200 diabetic patients, 113(56%) were 
males and 87(44%) were females. This shows that males are more prone 
to develop Diabetes mellitus. 
 
Overall incidence of hearing loss in diabetics: 
In our study, we evaluated the hearing loss in diabetic patients and their 
effect of hyperglycemia on hearing loss and it shows a 55% incidence of 
deafness. Friedman et al [18] observed an incidence of 55% hearing loss 
in patients with diabetes. Which is the same incidence found in our study.  
 
 Kakarlapudi et al [19] noted that patients with diabetes were more 
commonly known to have hearing loss (13.1%) when comparing to the 
control group who were non healthy subjects without diabetes. 
 
Wenget al [20] observed 67 patients with diabetes and found 44.8% 
among them had  hearing loss which was profound.  This is much lesser 
comparing to our study. 
DURATION OF DIABETES: 
In our study more number of patients with diabetes were found in 3-5 
years group, about 48%, followed by less than 2 years duration 31%. 
 
Comparing with, the duration of diabetes and hearing loss, more patients 
in the group 3-5 years had hearing loss, around 49%, followed by less 
than 2 years, around 32 years. Whereas only 20% patients were found to 
have hearing loss in 5-10 years group. 
 
In study it is seen that the duration of diabetes is not a significant criteria 
for developing sensoineural hearing loss. The p value is <0.05, making it 
statically significant. 
 
 A study by Celik et al [21] noted that as diabetes duration raised to more 
than 15 years, the hearing loss incidence also increased. The influence on 
hearing loss was not significant after 15 years. This change was not 
observed in our study as cases in our study were all mostly found to be 
less than 15 years. 
Overall severity of hearing in individual ear: 
 
It is noted that in the right ear 95 cases had normal hearing, 84 cases had 
mild hearing loss, 15 had moderate and 3 cases had moderately severe 
and severe hearing loss respectively. 
It is noted that in the left ear, 92 cases had normal hearing, 81 had 
minimal hearing loss, 16 had moderate loss 8 moderately severe, 2 with 
severe and 1 with profound hearing loss. Thus making it statically not 
significant (p>0.05). The above data was calculated taking the gender as 
consideration and compared the hearing. But no significant changes were 
noted in severity of hearing 
Taking into consideration the duration of diabetes, it is noted that in right 
ear maximum of 58 (30%) cases had hearing loss among the group 3-5 
years, among which 49 (25%) cases had mild hearing loss; 6 (3%) cases 
had moderate hearing loss and 3 cases (2%) had moderately severe loss, 
followed by 5-10 years group where 31 cases (16%) had hearing loss. 
 And in left ear it is noted that, maximum of 59 (30%) cases had hearing 
loss among the group 3-5 years, among which 44 (22%) cases had mild 
hearing loss; 8 (4%) cases had moderate hearing loss and 5 cases (3%) 
had moderately severe loss, followed by 5-10 years group where 32 cases 
(17%) had hearing loss. 
Thus, we conclude that predominantly mild sensorineural hearing loss is 
noted individually in both ears. The p value is <0.01, making it 
statistically significant.  
 
Overall severity of hearing loss: 
In our study, 72% of individuals with diabetes were noted to have mild 
sensorineural hearing loss, followed by 20% with moderate sensorineural 
hearing loss, 3% and 4% had moderately severe and severe sensorineural 
hearing loss. Only 1% had profound hearing loss. 
A study conducted by Rajendran et al showed a result similar to our 
study, The patients with diabetes reviled a high frequency loss which was 
bilateral and severity was from mild to moderate of sensorineural type 
and it was significant (73.3%) as compared to controls of similar age. 
 
Whereas Weng et al [14] noted that in 67 patients with diabetes who were 
examined, 44.8% of them had hearing loss which was profound 
 
Many studies were conducted to observe the pathogenesis of this 
sensorineural loss observed in diabetics. During this course many studies 
suggested that diabetes is a cause of  hearing loss. 
The probable mechanisms suggested were microangiopathy in the inner 
ear, neuropathy of cochlear nerve, or even a combination of both. Outer 
hair cell dysfunction and disruption of endolymphatic potential were 
noted in some studies. Some effects of diabetes on body tissue are 
thought to be correlating with the polyol pathway, where glucose is 
broken down to sorbitol. 
 Generally the accumulation of Sorbitol is observed in neuropathy as it 
causes a reduction in myo inositol levels which further leads to reduction 
in Na+ K+ ATPase activity [22]. 
 
 Makishima and Tanaka [23] demonstrated atrophy of the spiral ganglion 
over basal lamina and the middle turns of cochlea were severe in 
individuals with diabetes along with hearing loss which was sensorineural 
type. It was also noted that in the 8th nerve changes were present in the 
myelin sheath, which denoted degeneration and fibrosis of perineurium 
 
Jorgensen (1961) [24] in his study noted thickening in the vasa nervorum 
wall in the 8th nerve which lead to the development of acoustic 
neuropathy. 
 
In the study done by Wackym and Linthicum (1986) [25] noted small 
microangopathic variations in the regions of endolymphatic sac, basilar 
membrane and the stria vascularis. 
 
Van den Ouweland et al [26] observed mutational changes in the 
mitochondrial RNA. It was also observed that in a minor subset of 
patients, with diabetes inherited maternally showed some degree hearing 
loss which was sensorineural type. 
 
 
 Lisowska et al [27] in their study noted that in diabetic patients, there 
was abnormality in the function of outer hair cells in auditory brain stem 
responses. 
 
Fukushima et al [28] proposed that patients with type 2 Diabetes had 
changes in cochlea, leading to atrophy of stria vascularis and basal turn 
which was significant and which could be the likelihood of hearing loss 
in these patients. 
  
In our study, we conclude that after analyzing the audiograms of the 
diabetic patients, it is noted that they are more prone to develop mild to 
moderate sensorineural hearing loss. The duration of diabetes as well as 
sex of the individual were found not to have any effect on the incidence 
of hearing loss. 
 
 
  
LIMITATIONS OF STUDY 
 
1. The incidence of hearing loss in patients could have been more 
accurate with a larger group of study population. Only 200 diabetic 
patients were studied in study due to time and money constraints. 
 
2. As the study was carried out in already diagnoised cases of 
diabetes, the correlation with HBA1c values which denotes the 
control of diabetes, could not be considered as there was a financial 
constraint, because the test had to be done as an added 
investigation in our study. 
3. The occupations of the patients were not considered in the study 
which may influence the results of the audiogram this may be one 
of the drawback of the study.  
 
 
  
CONCLUSIONS 
 
1. The incidence of hearing loss among diabetics in our study is 55%. 
2. More number of patients had senorineural hearing loss which was 
mild, followed by moderate hearing loss. 
3. The incidence is greater in male patients. 
4. According to our study, the peak incidence of hearing loss was 
seen among 50 -55 yrs age group of people. 
5. In our study the duration of diabetes did not have an influence in 
developing sensorineural hearing loss. 
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ABBREVIATIONS 
 
PTA     -  Pure tone audiometery 
Hz       -  Hertz 
dB       -  Decibles 
SPL     -  Sound Pressure Level 
SRT    -  Speech Reception Threshold 
HL      -  Hearing loss 
SNHL   -  Sensorineural hearing loss 
CHL      -  Conductive hearing loss 
MODY    -  Maturity Onset Diabetes in Young 
DM     -  Diabetes Mellitus 
YLD    -  Years Lived with disability 
FDA    -  Food & Drud Association 
 
  
CONSENT FORM 
I, Prathula Sivakumar am carrying out a study on the topic: A study on 
prevalence of hearing loss as a complication of Diabetes mellitus as part 
of my research project being carried out under the aegis of the 
Department of: ENT 
 
 My research guide is: Dr.Palaninathan 
 
The justification for this study is: diabetic patients are more prone to 
complications of hyperglycaemia, as all body cells are exposed to high 
levels of plasma glucose. The organ of corti cells are important structures 
for hearing mechanism and turn out to be the potential target for damage, 
due to high glycemic levels, micro vascular compromise, their complex 
structure and arrangement. Thus screening of these patients at a higher 
risk of developing sensory neural hearing loss, will aid in early diagnosis 
and management 
 
The objectives of this study are:  
 
Primary Objective: To study the prevalence of hearing loss in diabetics.  
 
 
 
 
 
 
Sample size: 200.  
 
Study volunteers / participants are (specify population group & age 
group): Patients attending the outpatient services in department of ENT 
and diabetology in PSG IMSR between the age group 30 to 60 years. 
 
Location: PSG IMSR.  
 
We request you to kindly cooperate with us in this study. We propose 
collect background information and other relevant details related to this 
study. We will be carrying out:  
 
Initial interview (specify approximate duration): 2 minutes.  
 
Data collected will be stored for a period of fifteen years. We will not use 
the data as part of another study. 
 
Benefits from this study: Early diagnosis of hearing loss if present, early 
management. 
 
If you are uncomfortable in answering any of our questions during the 
course of the interview / biological sample collection, you have the right 
to withdraw from the interview / study at anytime. You have the 
freedom to withdraw from the study at any point of time. Kindly be 
assured that your refusal to participate or withdrawal at any stage, if you 
so decide, will not result in any form of compromise or discrimination in 
the services offered nor would it attract any penalty. You will continue to 
have access to the regular services offered to a patient. You will NOT be 
paid any remuneration for the time you spend with us for this interview / 
study. The information provided by you will be kept in strict confidence. 
Under no circumstances shall we reveal the identity of the respondent or 
their families to anyone. The information that we collect shall be used for 
approved research purposes only. You will be informed about any 
significant new findings - including adverse events, if any, – whether 
directly related to you or to other participants of this study, developed 
during the course of this research which may relate to your willingness to 
continue participation. 
 
Consent: The above information regarding the study, has been read by 
me/ read to me, and has been explained to me by the investigator. Having 
understood the same, I hereby give my consent to them to interview me. I 
am affixing my signature / left thumb impression to indicate my consent 
and willingness to participate in this study (i.e., willingly abide by the 
project requirements).  
 
 
Signature / Left thumb impression of the Study Volunteer / Legal 
Representative:  
 
Signature of the Interviewer with date:     
 Witness: 
 
 
  
 
  
 

  
 
 
 
